Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: A novel approach for patient selection

Annals of Thoracic Surgery

Volumn 76, Issue 1, 2003, Pages 187-193

  Brooks, Kelli R ^a   To, Kathleen ^a   Moore Joshi, Mary Beth ^a   Conlon, Debbi H ^a   Herndon II, James E ^a   D'Amico, Thomas A ^a   Harpole, David H ^a   Smythe, W Roy ^b   Daniel, Thomas M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUMC Box 3627 ^*

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; GROWTH FACTOR; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BEAM THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG DEGRADATION; DRUG RESPONSE; EVALUATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDIASTINUM LYMPH NODE; MEDICAL ASSESSMENT; METASTASIS; MISMATCH REPAIR; ONCOGENE NEU; PATIENT SELECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REGRESSION ANALYSIS; STANDARD; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE;

EID: 0038676365     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)00131-0     Document Type: Article

References (29)

1. Landis SH, Murray T, Bolden S, et al. Vital statistics of the United States, 1997. CA Cancer J Clin 1998;48:6–15.
2. Dillman RO, Seagren SL, Propert KL, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 2000;323:490–495.
3. Kridorian A, Rahmani R, Bromet M, Bore P, Cano JP. Pharmokinetics and metabolism of Navelbine. Semin Oncol 1989;16(Suppl 4):21–25.
4. Etievant C BJ, Druczynski A, Perrin D, Hill BT. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel vinca alkaloid, which participates in p-glycoprotein (P-gp.)- mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998;16:3–17.
5. Adams DJ, Knick VC. P-glycoprotein mediated resistance to 5-nor-anhydro-vinblastine (Navelbine). Invest New Drugs 1995;13:13–21.
6. Aria T, Yasuda Y, Takaya T, et al. Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small cell lung cancer. Cancer Detec Preven 2000;24:252–257.
7. Dive C. Avoidance of apoptosis as a mechanism of drug resistance. J Int Med 1997;242(Suppl 740):139–145.
8. Budman DR. Vinorelbine (Navelbine): a third generation vinca alkaloid. Cancer Invest 1997;15:475–490.
9. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1–6.
10. Prolla TA, Abui A, Bradley A. DNA mismatch repair deficient mice in cancer research. Semin Cancer Biol 1996;7:241– 247.
11. Aebi S, Kurdi-Haidar B, Fordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087–3090.
12. Crul M, Schellens JHM, Beijnen JH, Maliepaard M. Cisplatin resistance and DNA repair. Cancer Treat Rev 1997;23:341–366.
13. Brown R, Hirst G, Gallagher WM, McIlwrath AJ, Van der Zee A, Anthoney DA. hMLH1 expression, and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 1997;15:45–52.
14. D’Amico TA, Massey M, Herndon JE II, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients using 10 molecular markers. J Thor Cardiovasc Surg 1999;177:736–743.
15. Aloia TA, Harpole DH Jr., Moore MB, Reed CA, Allegra CA, D’Amico TA. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001;72:859–867.
16. Alexander D YT, Kato S, Kasai S. Histopathological assessment of multidrug resistance in gastric cancer: expression of p-glycoprotein, multidrug resistance associated protein, and lung-resistance protein. Jpn J Surg 1999;29:401–406.
17. Volm M. Multidrug resistance and its reversal. Anticancer Res 1998;18:2905–2918.
18. Kim YC PK, Kern JA, Park CS, Lim SC, Jang AS, Yang JB. The interactive effect of Ras, Her2, p53 and bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998;22:181–190.
19. Toso C LC. Vinorelbine: a novel vinca alkaloid. Am J Health-Syst Pharm 1995;52:1287–1304.
20. Gold Standard Multimedia I. Clinical Pharmacology Online, vol 2001. New York: Gold Standard Multimedia, Inc., 2000.
21. Kawasaki M NY, Kuwano K, Takayama K, Kiyohara C, Hara N. Immunohistochemically detected p53 and p-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 1998;34:1352–1357.
22. Galimberti S MA, Buttitta F, Carnicelli V, Pellegrini S, Bevilacqua G, Petrini M. Multidrug resistance related genes and p53 expression in human non-small cell lung cancer. Anticancer Res 1998;18:2973–2976.
23. Twentyman PR. Transport proteins in drug resistance: biology and approaches to circumvention. J Intern Med 1997; 242(Suppl 740):133–7.
24. Harpole DH Jr., Moore MB, Herndon JA, et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001;7:562–569.
25. Nakinishi YKM, Bai F, Takayama K, et al. Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer. Oncology 1999;57: 318–323.
26. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263–269.
27. Tannapfel A HH, Katalinic A, Fietkau RJ, Kühn R, Wittekind CW. Incidence of apoptosis, cell proliferation and p53 expression in renal cell carcinomas. Anticancer Res 1997;17: 1155–1162.
28. Herbst RS DNSA. Chemotherapy for advanced non-small cell lung cancer. Hem-Oncol Clin North Am 1997;11:473– 517.
29. D’Amico TA, Aloia TA, Herndon JE, et al. Molecular biologic substaging in patients with stage I non-small cell lung cancer: risk stratification according to gender and histologic subtype. Ann Thorac Surg 2000;69:882–886.